We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Conor Medsystems will have the opportunity to test and evaluate three Novartis pharmaceutical compounds for the potential development of a combination product utilizing a Novartis compound with Conor’s reservoir-based drug-eluting stents, the company announced.
In a decision prompted largely by difficult business conditions in the generics market, Alpharma is preparing to take a goodwill impairment charge on its U.S. generics business, the company said recently.
Interpharm has entered into two separate agreements with specialty drug-delivery technology company Tris Pharma that will increase Interpharm’s drug pipeline by up to 32 generic products over the next 30 months.
As part of its previously announced effort to divest its brand pharmaceutical operations, Andrx has inked a deal to sell the rights to its Fortamet and Altoprev products to First Horizon Pharmaceutical.
Pharmaceutical benefit manager (PBM) Medco Health Solutions has agreed to acquire Accredo Health for $2.2 billion — a deal that would create the nation’s largest specialty pharmacy business.
Mylan Laboratories has officially closed the door on its planned merger with King Pharmaceuticals, announcing late last month that it is not moving forward with the $4 billion deal.
As part of its previously announced effort to divest its brand pharmaceutical operations, Andrx has inked a deal to sell the rights to its Fortamet and Altoprev products to First Horizon Pharmaceutical.
Mylan Laboratories has officially closed the door on its planned merger with King Pharmaceuticals, announcing Feb. 25 that it is not moving forward with the $4 billion deal.
Biogen Idec and Elan suspended sales of their multiple sclerosis (MS) drug Tysabri Feb. 28 following reports that the product might have contributed to a pair of serious adverse events, including one patient death.
A top Democratic representative is prodding the SEC to take a harder look at how pharmaceutical companies disclose information about postmarketing studies to shareholders.